Article ; Online: Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.
European journal of endocrinology
2023 Volume 190, Issue 1, Page(s) S1–S11
Abstract: Objective: Hypogonadotropic hypogonadism is characterized by inadequate secretion of pituitary gonadotropins, leading to absent, partial, or arrested puberty. In males, classical treatment with testosterone promotes virilization but not testicular ... ...
| Abstract | Objective: Hypogonadotropic hypogonadism is characterized by inadequate secretion of pituitary gonadotropins, leading to absent, partial, or arrested puberty. In males, classical treatment with testosterone promotes virilization but not testicular growth or spermatogenesis. To quantify treatment practices and efficacy, we systematically reviewed all studies investigating gonadotropins for the achievement of pubertal outcomes in males with hypogonadotropic hypogonadism. Design: Systematic review and meta-analysis. Methods: A systematic review of Medline, Embase, Global Health, and PsycINFO databases in December 2022. Risk of Bias 2.0/Risk Of Bias In Non-randomized Studies of Interventions/National Heart, Lung, and Blood Institute tools for quality appraisal. Protocol registered on PROSPERO (CRD42022381713). Results: After screening 3925 abstracts, 103 studies were identified including 5328 patients from 21 countries. The average age of participants was <25 years in 45.6% (n = 47) of studies. Studies utilized human chorionic gonadotropin (hCG) (n = 93, 90.3% of studies), human menopausal gonadotropin (n = 42, 40.8%), follicle-stimulating hormone (FSH) (n = 37, 35.9%), and gonadotropin-releasing hormone (28.2% n = 29). The median reported duration of treatment/follow-up was 18 months (interquartile range 10.5-24 months). Gonadotropins induced significant increases in testicular volume, penile size, and testosterone in over 98% of analyses. Spermatogenesis rates were higher with hCG + FSH (86%, 95% confidence interval [CI] 82%-91%) as compared with hCG alone (40%, 95% CI 25%-56%). However, study heterogeneity and treatment variability were high. Conclusions: This systematic review provides convincing evidence of the efficacy of gonadotropins for pubertal induction. However, there remains substantial heterogeneity in treatment choice, dose, duration, and outcomes assessed. Formal guidelines and randomized studies are needed. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Male ; Chorionic Gonadotropin/therapeutic use ; Follicle Stimulating Hormone ; Gonadotropin-Releasing Hormone ; Gonadotropins/therapeutic use ; Hypogonadism/drug therapy ; Klinefelter Syndrome ; Spermatogenesis ; Testis ; Testosterone ; Young Adult | |||||
| Chemical Substances | Chorionic Gonadotropin ; Follicle Stimulating Hormone (9002-68-0) ; Gonadotropin-Releasing Hormone (33515-09-2) ; Gonadotropins ; Testosterone (3XMK78S47O) | |||||
| Language | English | |||||
| Publishing date | 2023-12-20 | |||||
| Publishing country | England | |||||
| Document type | Meta-Analysis ; Systematic Review ; Journal Article | |||||
| ZDB-ID | 1183856-5 | |||||
| ISSN | 1479-683X ; 0804-4643 | |||||
| ISSN (online) | 1479-683X | |||||
| ISSN | 0804-4643 | |||||
| DOI | 10.1093/ejendo/lvad166 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.147: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.